Latest / STOCK PICKS BY JOE COTTON CHAMPION STOCK PICKER / Two Low Priced Stocks with Big Upside

Transcript

Two Low Priced Stocks with Big Upside · STOCK PICKS BY JOE COTTON CHAMPION STOCK PICKER

• 0:02
  SPEAKER_00: Hi, and welcome to our podcast.
• 0:05
  SPEAKER_00: My name is Joe Cotton, and I'm a champion stock picker and expert market timer.
• 0:10
  SPEAKER_00: You can subscribe to my market letter, Cottons Technically Speaking, at our website, www.cottonstocks.net.
• 0:18
  SPEAKER_00: It comes with a risk-free 30-day 100% money-back guarantee from data purchase.
• 0:24
  SPEAKER_00: Nothing I say in this video is investment advice.
• 0:27
  SPEAKER_00: For investment advice, contact a registered investment advisor or certified financial planner.
• 0:34
  SPEAKER_00: Now, we have uh two very speculative stock picks today that we think have lots of upside.
• 0:42
  SPEAKER_00: The first one is Casia Therapeutics, symbol KZIA.
• 0:47
  SPEAKER_00: It closed at$7.87 on Monday, October 26th.
• 0:52
  SPEAKER_00: Guggenheim gave it a buy rating on October 21st with a$35 price target.
• 0:59
  SPEAKER_00: And League Rake Partners gave it an outperform rating on October 20th and a$30 price target.
• 1:06
  SPEAKER_00: It has a promising drug, Pexal, in clinical trials for both colorectal and breast cancer.
• 1:16
  SPEAKER_00: If you look at the chart, you can see it's made a one and a half year consolidation and appears to have made a two-week bottom triangle, and we expect it to move up from here.
• 1:28
  SPEAKER_00: It also had a bullish MACD crossover five days ago.
• 1:34
  SPEAKER_00: Per Fenvis, there are 11.34 million shares outstanding and 1.17 million shares short, which gives a short float of 11.94%, a fairly high number.
• 1:49
  SPEAKER_00: Current earnings show a loss of minus$6.82 per share, and a projected loss of minus$1.42 per share next year.
• 2:01
  SPEAKER_00: Insiders own 14.01%, relank the stock, and expect it to double within six months.
• 2:08
  SPEAKER_00: Bitech stocks are high risk.
• 2:10
  SPEAKER_00: If the drug in clinical trials isn't approved by the FDA, the stock can plummet and you can lose all or most of your investment.
• 2:19
  SPEAKER_00: Now, our second stock is Terrestrial Energy, Sybil IMSR, which closed at$2.94 on Monday, October 26th.
• 2:32
  SPEAKER_00: Lake Street gave it a buy rating and a$15 price target on October 21st, and Roth Capital gave it a buy rating and a$15 price target on September 22nd.
• 2:44
  SPEAKER_00: Now the company is a developer of Generation 4 nuclear plants that use its proprietary integral molten salt reactor.
• 2:56
  SPEAKER_00: ISMR plants are designed to be small and modular for industrial applications, such as petrochemical and chemical synthesis and data center operations.
• 3:09
  SPEAKER_00: The company has large projects in process, but as yet I found no nuclear plants in operation.
• 3:16
  SPEAKER_00: Mostly they are in the permitting stages, hence the large risk.
• 3:21
  SPEAKER_00: For finbiz.com, the company has 105.94 million shares outstanding and a float of 66.23 million shares.
• 3:31
  SPEAKER_00: 8.13 million shares are short, which gives a short float of 12.27%.
• 3:38
  SPEAKER_00: That's a high number.
• 3:40
  SPEAKER_00: Insiders own 37.48% of the shares.
• 3:44
  SPEAKER_00: No insider selling is shown.
• 3:46
  SPEAKER_00: Current earnings are minus 42 cents per share, and next year's earnings are estimated at a loss of minus 75 cents per share.
• 3:57
  SPEAKER_00: Now if you look at the chart, you can see the stock is way down from a year ago where it traded above$30 a share.
• 4:05
  SPEAKER_00: One day ago, it had a bullish MACD crossover, and it looks like it's making a two-week downward sloping triangle.
• 4:14
  SPEAKER_00: And we expect it to break out above the top trend line probably today and begin moving up.
• 4:20
  SPEAKER_00: We expect the stock to double in 90 days.
• 4:24
  SPEAKER_00: Want to thank you today for tuning in and best of luck, thank you.